Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096535 | 1.00 | TSHR (0.45) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL16426472 | 0.89 | TSHR (0.53) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL22113418 | 0.88 | TSHR (0.50) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL22096534 | 0.72 | TSHR (0.41) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL9965906 | 0.72 | ALDH1A1 (0.40) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL17001650 | 0.72 | ALOX15 (0.45) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL20816366 | 0.71 | TSHR (0.53) | TSHRALDH1A1MAPTTP53MEN1 | |
| Hydrochloric Acid SCHEMBL22528409 | 0.70 | ALDH1A1 (0.39) | TSHRALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL26685246 | 0.69 | ALDH1A1 (0.37) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL1013139 | 0.67 | TSHR (0.53) | TSHRALDH1A1MAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | TSHR 2909/4885ALDH1A1 1882/4885MAPT 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.